The mixed results from Kiniksa Pharmaceuticals, with a miss on EPS but a beat on sales, could lead to uncertain short-term stock price movements. The significant year-over-year sales growth indicates strong business performance, which might offset the negative impact of the EPS miss on investor sentiment. However, the larger than expected loss could concern investors about profitability, creating a neutral short-term outlook.